37 results about "Human Thrombin" patented technology

The present invention relates to compositions and methods for producing recombinant human thrombin using recombinant ecarin.

The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.

The present invention discloses affinity chromatographic process of separating and purifying plasmin. The process includes preparing affinity chromatographic medium and affinity chromatography. The preparation of affinity chromatographic medium includes the steps of: dissolving human fibrinogen in sterilized water at 35-40 deg.c, agarose in barbital sodium-HCl buffer solution, sterilizing and cooling; adding human thrombin and dropping into vinyl tetrachloride at 2-10 deg.c to form spherical grain; washing with ion-free water and maintaining at 35-40 deg.c for 1-2 hr; and adding glutaraldehyde to cross link. The affinity chromatography includes the steps of balancing the chromatographic column with the buffer liquid at 2-10 deg.c, adding the sample solution, rinsing with the buffer liquid and final eluting with the eluting solution. The present invention has high plasmin recovering rate and high plasmin purity.

A method for the preparation of a stable autologous or homologous coagulant from whole blood is disclosed. The direct precipitation of anticoagulated whole blood obviates the need for a plasma isolation step with unexpected results. The autologous or homologous coagulant produced by the method of the present invention demonstrated clotting times equivalent to commercially available bovine thrombin and human thrombin preparations, with improved kinetics of growth factor release from activated platelets over preparations of bovine thrombin.

The invention discloses a method for preparing human thrombin by activating human coagulation factor IX chromatography waste liquor. Human thrombin is prepared from a raw material which is waste liquor produced when a human coagulation factor IX is prepared by a chromatographic technology. The method specifically comprises the following steps: (1) obtaining a PCC (Prothrombin Concentration Complex) crude product from human blood plasma; (2) performing S / D inactivation; (3) obtaining a human coagulation factor IX crude product and chromatography waste liquor by chromatography; (4) activating the chromatography waste liquor; (5) purifying thrombin; (6) performing freeze-drying and dry-heat inactivation. According to the method, the F IX chromatography waste liquor is used as the raw material, and influence on the purification of F IX is prevented; the addition of any animal-derived substance in a waste liquor activation process is avoided; the method comprises two virus inactivation steps, so that high clinical safety is achieved.

The invention discloses a composite fat granule and a preparation method thereof. The composite fat granule comprises the components in the following proportions: 2ml of platelet-rich plasma, 1ml of human thrombin solution, (2+ / -0.5)*107 fat adipose-derived stem cells and 4ml of fat granules. Through the composite fat granule, the survival rate of transplanted fat can be improved, the long-term absorption rate is reduced, and situations, such as the formation of ectopic fibrotic nodules and the like can not occur.

The invention relates to a rosmarinic acid-containing thromboplastin time measuring reagent. The rosmarinic acid-containing thromboplastin time measuring reagent is composed of a Tris-HCl buffer containing 25 U / ml of human thrombin, 2% of bovine serum albumin, 1.5 mM of rosmarinic acid, 0.05% of sodium azide, 3.5% of methionine, 1.5% of PEG, 3% of mannitol, 2.5% of maltose and 10 mM of calcium chloride, wherein percentage is mass-volume ratio, and a pH value is 7.4. A preparation method of the reagent comprises the following steps: preparing the buffer with the pH value being 7.4 and Tris concentration being 50 mM, adding BSA with final concentration being 2%, 1.5mM of rosmarinic acid with final concentration being 2%, triazacyclononane with final concentration being 0.05%, methionine with final concentration being 3.5%, PEG with final concentration being 1.5%, mannitol with final concentration being 3%, maltose with final concentration being 2.5%, and 10mM of calcium chloride in the buffer, wherein, besides calcium chloride, the unit of the materials is mass-volume fraction; filtering a mixed liquor with a 0.22-micrometer filter membrane, and adding a human thrombin freeze-drying preparation in a filtrate so that the concentration of human thrombin in a final filtrate is 25 U / ml, and obtaining a TT reagent. According to the invention, rosmarinic acid is taken as a stabilizing agent, so that antioxidation performance and stabilization performance of the thromboplastin time measuring reagent can be obviously increased.

The invention discloses an isothymidine-modified thrombin nucleic-acid aptamer, and a preparation method and application thereof, and belongs to the field of biomedicine. By doping isothymidine shown as a chemical formula I and / or II into synthesized thrombin nucleic-acid aptamer, the isothymidine-modified thrombin nucleic-acid aptamer is obtained. Experiments prove that the human thrombin nucleic-acid aptamer modified by employing the method is capable of relatively well recognizing thrombin, is relatively strong in bonding force and has relatively strong anticoagulation effect, and therefore the isothymidine-modified thrombin nucleic-acid aptamer is hopeful to be prepare a high-efficiency high-selectivity anticoagulation medicine with low toxic and side effects.

The invention relates to a general formula and physiologically acceptable salts thereof: A-L-B-L'-C, wherein A and B are binding sites with thrombin, C is a binding site with a platelet GPIIb / IIIa receptor, L is a first linking group, and L' is a second linking group. The invention also relates to a preparation method and application of the compound. The invention provides an anticoagulant and antiplatelet GPIIb / IIIa receptor multi-target compound, which has good in-vitro human thrombin inhibition activity, in-vitro platelet GPIIb / IIIa receptor inhibition effect, in-vitro / in-vivo anti-platelet aggregation, in-vivo anticoagulant and antithrombotic effects; and the multi-target compound can be clinically used for preventing and treating peripheral artery thrombosis and arteriovenous bypass thrombosis, treating thrombosis in acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), and preventing and treating cerebral arterial thrombosis.

The invention relates to a general formula and physiologically acceptable salts thereof: A-L-B-L'-C, wherein A and B are binding sites with thrombin, C is a binding site with a platelet GPIIb / IIIa receptor, L is a first linking group, and L' is a second linking group. The invention also relates to a preparation method and application of the compound. The invention provides an anticoagulant and antiplatelet GPIIb / IIIa receptor multi-target compound, which has good in-vitro human thrombin inhibition activity, in-vitro platelet GPIIb / IIIa receptor inhibition effect, in-vitro / in-vivo anti-platelet aggregation, in-vivo anticoagulant and antithrombotic effects, and can be used for preparing antithrombotic drugs. The traditional Chinese medicine composition can be clinically used for preventing and treating peripheral artery thrombosis and arteriovenous bypass thrombosis, treating thrombosis in acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), and preventing and treating cerebral arterial thrombosis.

This invention relates to a novel method for producing di-chain proteins for use in humans from single-chain precursors, including di-chain clostridial neurotoxins. The method comprises the step of expressing a nucleic acid sequence encoding a single-chain precursor comprising a thrombin-cleavage site and the step of cleaving the single-chain precursor with a human factor Xa or a human thrombin, particularly a human thrombin drug product authorized for human therapeutic use. The invention further relates to novel di-chain clostridial neurotoxins and nucleic acid sequences encoding such novel di-chain clostridial neurotoxins.

The invention relates to a general formula and physiologically acceptable salts thereof: A-L-B-L'-C, wherein A and B are binding sites with thrombin, C is a binding site with a platelet GPIIb / IIIa receptor, L is a first linking group, and L' is a second linking group. The invention also relates to a preparation method and application of the compound. The invention provides an anticoagulant and antiplatelet GPIIb / IIIa receptor multi-target compound, which has good in-vitro human thrombin inhibition activity, in-vitro platelet GPIIb / IIIa receptor inhibition effect, in-vitro / in-vivo anti-platelet aggregation, in-vivo anticoagulant and antithrombotic effects, and can be used for preparing antithrombotic drugs. The traditional Chinese medicine composition can be clinically used for preventing and treating peripheral artery thrombosis and arteriovenous bypass thrombosis, treating thrombosis in acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), and preventing and treating cerebral arterial thrombosis.

The invention provides a high expression and production method of recombinant human thrombin in animal cells. Specifically, the invention provides a fusion gene and a fusion protein coded by the same. The gene contains signal peptide sequence of human protein C and Gla structural domain deleted human prothrombin gene sequence, and can enhance expression level of human prothrombin-2. The invention also discloses a method for employing a recombinant expression vector containing the above nucleotide sequence to express and produce human prothrombin in animal cells. The invention also discloses a method for producing recombinant human thrombin by purification and activation. The recombinant human thrombin produced by the invention has biological activity satisfying treatment of correlative clinic diseases.